CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 126 enrolled
Drug / intervention
Tradipitant +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03772340
NCT03772340Phase 2Completed
CompareCT.gov

Motion Sifnos: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness During Travel

Vanda Pharmaceuticals·interventional·Posted Dec 11, 2018·Updated May 9, 2025

In Brief

A Phase 2 clinical trial evaluating Tradipitant and Placebo for Motion Sickness. Completed, enrolled 126 participants across 1 site.

Detailed Summary

Randomized, double-blind, placebo-controlled investigating the efficacy of tradipitant in the treatment of motion sickness.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMotion Sickness
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedDec 11, 2018
Enrollment StartDec 20, 2018
Primary CompletionJun 6, 2019
Study CompletionJun 27, 2019
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 7.6 years ago

Interventions

Tradipitantdrug

Oral capsule

Placebodrug

Oral capsule